Dr. Costa has previously worked with companies like Merck & Co., Celgene, Novartis and more recently at Servier Pharmaceuticals. Mr. Jonas has extensive leadership experience in founding and growing public companies, and has sold multiple businesses in deals worth both hundreds of millions and billions of dollars. Mike holds a BioMedical Engineering degree and MBA from University of Illinois at Chicago. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Sol J. Barer, Chairman of the Board of Teva Pharmaceuticals, Chairman of Centrexion Therapeutics, Lead Director of Contrafect Corp, Chairman of Neximmune, and Board member of 3DBiotherapeutics and Cerecor, Founding Chair of the Hackensack Meridian Center for Discovery and Innovation and advisor to the Israel Biotech Fund. Prior to ZyVersa, Deepak worked at Sucampo Pharmaceuticals, which was acquired by Mallinckrodt. Mr. Jonas, who has served as the Company's Chairman and CEO since its inception, will continue as Chairman of the Board and remain an active member of the management team. He earned his Ph.D. from the University of London, and a DIC from the University of London Imperial College of Science and Technology. Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO Leadership Team Will Build on Pharma … Dr. Shorr has a 40-year track record in drug discovery from concept through approval and market launch. Prior to Spark, Priya worked in clinical operations roles with increasing responsibility at Jazz Pharmaceuticals and at Teva Pharmaceuticals. During his graduate work, he focused on dissecting a GPCR signaling mechanism involved in cardiac hypertrophy. Dr. Scheller was previously a professor at Stanford University Medical Center (1982-2001), and an Investigator at the Howard Hughes Medical Institute. At Enzon, Dr. Shorr was responsible for co-development with Schering-Plough of the blockbuster drug, PEG INTRON A, for the treatment of hepatitis and certain forms of melanoma. Mr. Jonas is the Founder and Chairman of IDT Corporation (NYSE: IDT), Genie Energy (NYSE: GNE), and IDW Media (OTC: IDWM). Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613 ® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Dr. Haque provides leadership and oversight of all global safety risk management and pharmacovigilance activities for Rafael Pharmaceuticals. Jenna brings nearly two decades of experience in finance from the pharmaceuticals industry. Priya earned her undergraduate degree from George Washington University and completed her Master’s Degree in Molecular Biotechnology at the University of Pennsylvania. Dr. Scheller is the Chief Science Officer of Google-backed 23andMe. Mr. Drillick is the Chief Financial Officer for Eastern Properties. He earned his B.S. He is also the Principal Founder of Idenix Pharmaceuticals, Inc. and a Co-Founder of Pharmasset, Inc., both of which had successful multi-billion dollar exits. Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters and conference proceedings and has more than 150 inventions with more than 300 issued and pending patents worldwide. Dr. Pardee is an Associate professor and the Director of Leukemia Translational Research at the Comprehensive Cancer Center of Wake Forest Baptist Medical Center. Sanjeev will discuss the status of our company, milestones and #clinicaltrial launches achieved throughout the year, despite the challenges amid the #COVID19 pandemic. Science, Technology & Engineering Facebook is showing information to help you better understand the purpose of a Page. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Prior to joining Eastern Properties, Mr. Drillick was a manager at the Federal Reserve Bank of New York, responsible for the Bank’s capital and operating budgets. About Rafael Pharmaceuticals, Inc. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, Named Finalist for The 2019 EY Entrepreneur Of The Year® Award in New Jersey Learn More June 4, 2019 Rafael Pharmaceuticals to Present at the 2019 Jefferies Global Healthcare Conference Learn More May 16, 2019 Dr. Hu earned his Ph.D. in Pharmaceutical Sciences from Shenyang Pharmaceutical University. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has entered into an out-licensing agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), a pharmaceutical company committed to creating innovative medicines. 8 talking about this. He was the co-discoverer of the first Altered Metabolism Directed (AMD) compounds. He earned his M.D. and M.B.A. in Business Administration from SUNY Buffalo. Deepak Tiwari has over 25 years of CMC experience in drug substance and drug product manufacturing. Rafael Pharmaceuticals, Inc. operates as a clinical-stage, metabolic oncology therapeutics company. He has previously served as VP of Science and Technology at Enzon Pharma, VP of Science and Technology and Chief Scientist at United Therapeutics, and Associate Director of Molecular Pharmacology at SmithKline Beecham. 16, … Under his leadership, Rafael has made significant progress towards strategy, business portfolio, clinical development (leading to two Phase III programs and several Orphan Designations) and has enhanced its discovery portfolio. in Microbiology from the University of Illinois, and a Ph.D. in Biochemistry and Molecular Biology from Harvard University. He earned his B.S. He has a Bachelors degree from Brooklyn College and a Masters degree from the New York University School of Engineering and Science. Through its … He was also the Founder and controlling shareholder of Straight Path Communications, Inc (NYSE: STRP), which was acquired by Verizon for $3.1 Billion. Fast forward and I now serve as the president and CEO of Rafael Pharmaceuticals, a leading company in the growing field of cancer metabolism-based therapeutics. He has played important role in development and life-cycle management for several blockbuster products including Revlimid in entire Latin American region.
Gift Card Message For Friend, Cash Advance In Hotel, Mang Inasal Promotion Strategy, Mira Car Price In Pakistan 2012, Sarah Utterback Net Worth, Abu Dhabi International Book Fair, The Stationery Shop Spoiler, Port Strategy Media Pack, What Is Nft, Sugar Land Skeeters Hat, Walmart Corporate Gift Cards, How To Use Manufacturer Coupons Online Walmart, Guided By Voices Music Videos,